Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marina Chiara Garassino, Delvys Rodriguez-Abreu, Shirish M. Gadgeel, Emilio Esteban González, Enriqueta Felip, Flavia De Angelis, Manuel Domine, Maximilian J. Hochmair, Steven Francis Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Martin Reck, Rina Hui, Edward B. Garon, Michael J. Boyer, Jing Yang, Thomas A. Burke, Maria Catherine Pietanza, Leena Gandhi
Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Universitario Insular de Gran Canaria, University of Michigan, Hospital Universitario Central de Asturias, Vall d'Hebron Institute of Oncology, Hospital Universitario Fundación Jiménez Díaz, Otto Wagner Hospital, Sanford Health, Sunnybrook Health Science Centre, Soroka Medical Center, Clalit Health Services, German Center for Lung Research, The University of Sydney, Westmead Hospital, University of California, Los Angeles, Chris O’Brien Lifehouse, Merck & Co., Inc., Rahway, NJ, USA (United States), NYU Langone’s Laura and Isaac Perlmutter Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890591279